Molecular In-Depth Characterization of Chondrosarcoma for Current and Future Targeted Therapies
OPEN ACCESS
Loading...
Author / Producer
Date
2023-05-01
Publication Type
Review Article
ETH Bibliography
yes
Citations
Altmetric
OPEN ACCESS
Data
Rights / License
Abstract
Chondrosarcoma (CHS) are heterogenous, but as a whole, represent the second most common primary malignant bone tumor entity. Although knowledge on tumor biology has grown exponentially during the past few decades, surgical resection remains the gold standard for the treatment of these tumors, while radiation and differentiated chemotherapy do not result in sufficient cancer control. An in-depth molecular characterization of CHS reveals significant differences compared to tumors of epithelial origin. Genetically, CHS are heterogenous, but there is no characteristic mutation defining CHS, and yet, IDH1 and IDH2 mutations are frequent. Hypovascularization, extracellular matrix composition of collagen, proteoglycans, and hyaluronan create a mechanical barrier for tumor suppressive immune cells. Comparatively low proliferation rates, MDR-1 expression and an acidic tumor microenvironment further limit therapeutic options in CHS. Future advances in CHS therapy depend on the further characterization of CHS, especially the tumor immune microenvironment, for improved and better targeted therapies.
Permanent link
Publication status
published
External links
Editor
Book title
Journal / series
Volume
15 (9)
Pages / Article No.
2556
Publisher
MDPI
Event
Edition / version
Methods
Software
Geographic location
Date collected
Date created
Subject
Sarcoma; Chondrosarcoma; Immune; Tumor microenvironment; Extracellular matrix; Tumor profile